Company intelligence / Profile preview

AMIVAS

Frederick, Maryland, United Statesamivas.com ↗

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Amivas has successfully received regulatory approvals for Artesunate for the treatment of severe malaria from the FDA, MHRA, and EMA. Their product Artesunate AMIVAS is the first and only licensed severe malaria treatment in Europe and the UK.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

artesunate

Approved

Partnerships

Nordic Prime (distributor in Denmark, Finland, Sweden and Norway)

Beyond the preview

Go deeper on AMIVAS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMIVAS.